Suppression of CLDN4 expression was shown to reduce mesenchymal transformation, as well as inhibit GBM cell invasion, migration, and tumor growth both in vitro and in vivo. Functional analyses revealed that CLDN4 is involved in modulating the tumor necrosis factor alpha (TNF-α) signaling pathway. The gene discussed is TNF; the disease is glioblastoma.